Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Pieris Pharmaceuticals Inc News

    11,28 € +3,30% +0,36 €
    22.04.24 13:35:35 L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A40A3W
    ISIN: US7207952026
    US-Symbol: PIRS
    Typ: Aktie

    Pieris Pharmaceuticals Inc News

    27.09.23 - PR Newswire
    Thinking about buying stock in Soleno Therapeutics, Lovesac, Pieris Pharmaceuticals, Lithium Americas, or Fisker?
    Thinking about buying stock in Soleno Therapeutics, Lovesac, Pieris Pharmaceuticals, Lithium Americas, or Fisker? PR Newswire
    08.09.22 - ACCESSWIRE
    Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
    BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
    24.08.22 - ACCESSWIRE
    Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
    BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    04.08.22 - ACCESSWIRE
    Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
    COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT
    28.07.22 - ACCESSWIRE
    Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
    BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    02.06.22 - ACCESSWIRE
    Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
    BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    18.05.22 - ACCESSWIRE
    Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
    BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    11.05.22 - ACCESSWIRE
    Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
    Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT
    04.05.22 - ACCESSWIRE
    Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
    BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    23.04.22 - The Motley Fool
    3 riskante Aktien mit großem Potenzial
    Viele Menschen wollen nur „sichere“, „ausgereifte“ oder „langweilige“ Aktien besitzen und ignorieren die Chancen auf der riskanten Seite des Aktienuniversums. Auf diese Weise ...
    01.03.22 - ACCESSWIRE
    Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
    COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST
    23.02.22 - ACCESSWIRE
    Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
    BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
    14.01.22 - ACCESSWIRE
    Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
    BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    03.01.22 - ACCESSWIRE
    Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
    BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    11.11.21 - ACCESSWIRE
    Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences
    BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
    08.11.21 - ACCESSWIRE
    Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
    BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel ...
    02.11.21 - ACCESSWIRE
    Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
    Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDT
    26.10.21 - ACCESSWIRE
    Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021
    BOSTON, MA / ACCESSWIRE / October 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
    06.10.21 - ACCESSWIRE
    Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer
    BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    09.09.21 - ACCESSWIRE
    Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
    BOSTON, MA / ACCESSWIRE / September 9, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...

    Newssuche

    Videos

    30.04.24 -9,41%
    Technical Trading: Sojabohnen Long bis Juli
    Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »